Stay updated with breaking news from Almeda Ventures. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The new funds will be used for US commercialization of the BioProtect Balloon Implant System, which recently received FDA clearance for rectal protection during radiation therapy for prostate cancer.
The funding comes three months after the company announced it added AI-enabled imaging features and new indications expanding xvision's use to the whole spine.
The Israeli-founded company has marked its record 4,000th US patient treated with the xvision Spine System.
Walgreens earnings disappoint, Augmedic's big venture-capital haul and more in today's Health Pulse.
Augmedics closed a Series D financing worth $82.5 million just after recording the 4,000th U.S. patient treated with Xvision.